相关实验视频

Updated: Jul 20, 2025

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

DEF6 ((差异性表 homolog) 通过RAC1加剧了病理性心脏缩

Yan Sun¹, Changlu Xu², Zhongxiu Jiang³

¹Department of Gastroenterology, Shengjing Hospital of China Medical University, 110022, Shenyang, Liaoning Province, China.

Cell death & disease

|July 31, 2023

概括

在FDCP 6同源 (DEF6) 中差异表达,通过激活Rac1和MEK1/2-ERK1/2通路,促进病态心脏缩. 缺DEF6可以缓解心脏缩,这表明它是心力衰竭的潜在治疗点.

科学领域:

心血管生物学心血管生物学
分子细胞生物学分子细胞生物学
生物化学生物化学

背景情况:

病理性心脏缩是一种复杂的疾病,其机制不完全理解.
在FDCP 6同源 (DEF6) 中差异表达,涉及各种细胞过程,但其在心脏缩中的作用尚不清楚.

研究的目的:

研究DEF6在病理性心脏缩中的作用和潜在机制.

主要方法:

评估了高性心脏和心肌细胞中的DEF6表达.
使用心脏缩 (横向大动脉收缩) 的小鼠模型,与DEF6缺乏和心肌细胞特异性过度表达.
在实验室研究中使用烯诱导的心肌细胞缩.
研究了包括MEK1/2-ERK1/2和Rac1相互作用在内的信号通路,使用共免疫沉,GST拉回和活动测试.
使用药理抑制剂和突变蛋白质的验证结果.

主要成果:

在高性心脏和心肌细胞中,DEF6的表达被上调.
在体内,DEF6缺乏减轻了心脏缩,纤维化,扩张和功能障碍.
DEF6过度表达加剧了心脏缩.
DEF6 knockdown 抑制了 fenilephrine 诱导的心肌细胞缩,而过度表达则促进了它.
DEF6直接与Rac1相互作用,调节其活动.
MEK1/2-ERK1/2通路由DEF6激活,调解其益高缩作用.
Rac1和MEK1/2-ERK1/2激活对于DEF6引起的心脏缩至关重要.

结论:

DEF6在病理性心脏缩中起到有害的调节作用.
DEF6通过激活Rac1和MEK1/2-ERK1/2信号通路来促进心脏缩.
DEF6代表了治疗与心脏缩相关的心力衰竭的潜在治疗标.

更多相关视频

Transverse Aortic Constriction in Mice

Transverse Aortic Constriction in Mice

Published on: April 21, 2010

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

相关概念视频

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

Pathophysiology of Heart Failure

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...

Cardiomyopathy IV: Restrictive Cardiomyopathy

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...